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OBJECTIVE — To evaluate whether asymptomatic bacteriuria (ASB) is more common in
patients with diabetes than among control subjects. In addition, we wanted to clarify the clinical
signiﬁcance of ASB in patients with diabetes.
RESEARCH DESIGN AND METHODS — We conducted a systematic review and
meta-analysisofpublisheddatasince1966.Twenty-twostudiesfulﬁlledtheinclusioncriteriaof
the meta-analysis.
RESULTS — ASB was present in 439 of 3,579 (12.2%) patients with diabetes and in 121 of
2,702 (4.5%) healthy control subjects. ASB was more common both in patients with type 1
diabetes (odds ratio 3.0 [95% CI 1.1–8.0]) and type 2 diabetes (3.2 [2.0–5.2]) than in control
subjects. The point prevalence of ASB was higher in both women (14.2 vs. 5.1%; 2.6 [1.6–4.1])
andmen(2.3vs.0.8%;3.7[1.3–10.2])aswellasinchildrenandadolescents(12.9vs.2.7%;5.4
[2.7–11.0]) with diabetes than in healthy control subjects. Albuminuria was more common in
patients with diabetes and ASB than those without ASB (2.9 [1.7–4.8]). History of urinary tract
infections was associated with ASB (1.6 [1.1–2.3]).
CONCLUSIONS — WewereabletoshowthattheprevalenceofASBishigherinallpatients
with diabetes compared with control subjects. We also found that diabetic subjects with ASB
more often had albuminuria and symptomatic urinary tract infections.
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A
s the prevalence of both type 1 dia-
betes and type 2 diabetes increases
world wide, factors associated with
diabetes and its complications become
more important (1,2). Asymptomatic
bacteriuria (ASB) refers to the presence of
bacteriainbladderurineinanasymptom-
atic individual. Usually, samples are
collected indirectly by clean-voided mid-
stream urine, and growth of the same
uropathogen (10
5 cfu/ml) in two
consecutivespecimensisconsideredtobe
a signiﬁcant indication of the presence of
bacteriainbladderurine(3).ASBisfound
in 2–5% of healthy adult women, is quite
unusual in healthy men, and has been
claimed to be three to four times more
common in women with diabetes than in
healthy women (3). A prevalence as high
as 30% in diabetic women has been re-
ported (4).
ASB is considered clinically signiﬁ-
cantandworthtreatingduringpregnancy
because treatment effectively reduces the
risk of pyelonephritis and preterm deliv-
ery(5,6).AlthoughASBhasbeenfoundto
associate with increased risk of hospital-
ization for urosepsis in a prospective ob-
servational study among women with
diabetes (7), the treatment of ASB in one
randomized controlled trial did not re-
ducetheriskofsymptomaticurinarytract
infection (8). Associations between ASB,
metabolic control of diabetes, and im-
paired renal function have been brought
up repeatedly (9–15). To evaluate
whether ASB is truly more common in
patientswithdiabetesthanamongcontrol
subjects and to clarify the clinical signiﬁ-
cance of ASB in diabetic subjects we did a
systematic literature search and per-
formed a meta-analysis of the published
data.
RESEARCH DESIGN AND
METHODS— We performed a litera-
ture search in PubMed for the years
1966–2007 using the following MeSH
terms: “asymptomatic bacteriuria” and
“diabetes” in order to ﬁnd all the articles
that considered epidemiology, risk fac-
tors, and prognosis of ASB in patients
with diabetes. Altogether, 112 hits were
found.Reviews,commentaryarticles,and
editorials were excluded. On the basis of
the title and abstract, 45 articles were
found to be original-research articles on
the selected topic. All members of the
studygroupreadthese45articles.Studies
where ASB was deﬁned as growth of one
or two bacteria species for 10
5 cfu/ml
urine in one or more samples taken from
asymptomaticpatientswereincluded.Af-
ter excluding 24 articles in which study
design,presentation,orreportingwasnot
adequate, 21 articles were ﬁnally ac-
cepted and analyzed (Fig. 1). Of the non-
English articles, only abstracts in English
were reviewed.
We focused on the point prevalence
of ASB in diabetic patients and control
subjects and the associations of ASB and
speciﬁc risk and prognostic factors
among people with diabetes. Analyses
were performed using the Comprehen-
sive Meta-Analysis Program, version
1.0.25. Heterogeneity was assessed and
quantiﬁed by calculating I
2 (inconsis-
tency) values. Without the heterogeneity
(test for inconsistency not signiﬁcant),
pooled estimates of odds ratios (ORs) or
effect sizes and 95% CIs for the estimates
were derived using a ﬁxed-effects model;
otherwise, a random-effects model was
used (16). The possibility of publication
bias was assessed with funnel plots (not
shown). The analyses were performed
separately for women and men and for
patients with type 1 diabetes and type 2
diabetes, whenever possible. The quality
ofthearticleswasassessedbyallmembers
ofthestudygroup,usingascalefrom1to
5, and the summary scoring was then de-
cided after a discussion on the ﬂaws and
biases of the study. Because using one ﬁg-
ure indicative for the quality of included
studieshasbeenshowntobeproblematic
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included in the ﬁnal analyses (17).
RESULTS— Twenty-two studies ful-
ﬁlled the inclusion criteria of the meta-
analysis (Table 1). The design was cross-
sectionalin16andfollow-upin5studies,
whereas 10 studies comprised only
women. The mean quality score of the
studies included in the analyses was 2.6
(range 1–4). The only randomized inter-
vention trial was evaluated separately (8).
In the pooled data, ASB was present
in 439 of 3,579 (12.2%) patients with di-
abetesandin121of2,702(4.5%)healthy
control subjects. ASB was more common
in both patients with type 1 diabetes (OR
3.0 [95% CI 1.1–8.0]) and type 2 diabe-
tes (3.2 [2.0–5.2]) than in control sub-
jects. The point prevalence of ASB was
higherinbothwomen(14.2vs.5.1%;2.6
[1.6–4.1]) and men (2.3 vs. 0.8%; 3.7
[1.3–10.2]) with diabetes than in healthy
control subjects (Figs. 2 and 3). There
were only two trials (12,18) that included
children and adolescents and comprised
683 subjects and was published by the
same study group. In these surveys, ASB
was more common in children and ado-
lescents with diabetes (12.9%) than in
healthy control subjects (2.7%; 5.4 [2.7–
11.0]) (Fig. 4).
The effect of the duration of diabetes
on the point prevalence of ASB was re-
ported in four studies (9,10,13,19) all
comprising only women. The mean dura-
tion of diabetes was longer in patients
with ASB than in those without ASB
(pooled difference 0.17 years [95% CI
0.03–0.31];P0.01).ThemeanA1C,as
a measurement of glycemic control in di-
abetes, did not differ in diabetic subjects
with ASB compared with those without
ASB (pooled difference 0.21 [0.07 to
0.50]; P  0.14).
The mean creatinine level did not dif-
fer in diabetic subjects with or without
ASB in three cross-sectional surveys
(pooled difference 0.21 mol/l [95% CI
0.3 to 0.8]; P  0.36) (7,11,19). Asso-
ciation of proteinuria and ASB was stud-
ied in three trials (10,19,20). Proteinuria,
deﬁned as 30 mg/24 h in two of the
studiesandaspresenceofmacroalbumin-
uria in one study, was more common in
patientswithdiabetesandASBthanthose
without ASB (OR 2.9 [95% CI 1.7–4.8];
P  0.0001) (Fig. 5).
Renal function was measured with
glomerulus ﬁltration rate (GFR) in two
studies, both of which included only
women with diabetes. In the cross-
sectional survey, there was no difference
in GFR values between diabetic subjects
with and without ASB, but in a 6-year
follow-upstudytheGFRvaluesdecreased
more in patients with diabetes and ASB
thaninthosewithoutASB(14vs.9%,P
0.03) (9,15). In multivariate analyses ad-
justed for age, length of follow-up, dura-
tion of diabetes, and microalbuminuria at
baseline, the difference was no longer sta-
Figure 1—Flowchart of the literature search.
Figure 2—Forest plot of 12 studies on the prevalence of ASB in women with diabetes and healthy control subjects. Because of the heterogeneity of
the studies (I2 63%, P  0.001), the results of the random-effects model are presented.
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was more common in women with diabe-
tes and ASB (54%) than without ASB
(37%), but this difference was not statis-
tically signiﬁcant when adjusting for con-
founding variables in logistic modeling
(15).
In two cross-sectional surveys
(10,11)inwhichthehistoryofhavinghad
a urinary tract infection (UTI) ever in the
past was compared in diabetic subjects
with and without ASB, positive UTI ana-
mnesis was associated with ASB (OR 1.6
[95% CI 1.1–2.3]). In follow-up studies
that included both women and men,
symptomatic UTIs tended to be more
common in diabetic subjects with ASB
thaninthosewithoutASB(2.8[0.8–9.8])
(7,14,21,22).
CONCLUSIONS — In this meta-
analysis of observational studies, we were
able to show that the prevalence of ASB
was three times higher in all patients with
diabetes compared with control subjects.
We also found that diabetic subjects with
ASB more often had albuminuria and
symptomatic UTIs than those without
ASB. Only one randomized controlled
trial on the effect of active treatment of
ASB on occurrence of symptomatic UTIs
has been performed (8).
Whether glucosuria, as such, could
increase the rate of ASB is unclear. Even
though adding glucose to urine enhances
the growth of bacteria in vitro, the associ-
ationhasnotbeenveriﬁedinvivo(23).In
this meta-analysis, A1C was slightly
higher in diabetic subjects with ASB than
in those without ASB, but the difference
was neither statistically nor clinically sig-
niﬁcant. Thus, it seems unlikely that ASB
would be just a consequence of a poor
metabolic control of diabetes.
Urinary albumin is an important
marker of diabetic nephropathy. We
found that albuminuria was more com-
mon in diabetic subjects with than with-
out ASB. The presence of bacteriuria, as
such, does not seem to interfere with uri-
nary albumin measurements. Kramer et
al. (24) measured urine albumin concen-
trations in the same 81 diabetic individu-
als during ASB and with sterile urine, and
no statistically signiﬁcant differences
were found.
Systematicreviewsandmeta-analyses
of observational studies are very sensitive
to biases atrributed to confounding fac-
tors. Meta-analyses of observational stud-
ies are good in developing new
hypotheses that then have to be tested in
intervention studies. In our meta-
analysis, we were able to verify the higher
incidence of ASB in diabetic compared
with control subjects. Associations
between ASB and important clinical
outcomes, such as occurrence of symp-
tomatic UTIs and complications of diabe-
tes,havebeenevaluatedinseveralsurveys
(10,11,13–15), but the conclusion has
been that screening of ASB in diabetes is
not beneﬁcial. Lack of association has
beeninterpretedasanevidenceforequal-
ity (6). In this case, ASB does not cause
any clinical consequences, and most of
the research ﬁndings would show this.
However, by chance alone, there would
also be ﬁndings showing both negative
and positive associations with ASB and
clinicalendpoints.Yettherearereportsof
no association and reports showing posi-
tiveassociationsbetweenASBandclinical
outcomes but no real contradictory re-
ports. This was seen also in our meta-
analysis, in which because a small
number of studies and patients were in-
cluded, only the association between al-
buminuria and ASB reached statistical
signiﬁcance. The lack of contradictory re-
ports may well be because of publication
bias, but we suggest that the associations
of ASB and clinical outcomes should be
further tested in prospective trials to bet-
ter deﬁne the questions raised in this
meta-analysis.
ASB is not a stable phenomenon but
ﬂuctuates over time even without any in-
terventions.ThepathophysiologyofUTIs
is unclear, but it is probable that the bio-
logic reasons for asymptomatic and
symptomatic urinary infections are simi-
lar. In the randomized controlled trial,
routinescreeningandtreatmentofASBin
diabeticwomendidnotchangetheoccur-
renceofsymptomaticUTsIorhospitaliza-
tion because of UTIs (8). Harding et al.’s
(8) trial is a landmark study in this ﬁeld,
but only women were included, mostly
with type 2 diabetes. It is important to
repeat these results and also include men
and adolescents in the material. Alto-
gether, the only way to thoroughly clarify
the signiﬁcance of ASB in patients with
diabetes is to perform high-quality pro-
spective studies on screening and treating
ASB, with UTIs, metabolic control, and
Figure 4—Forest plot of two studies on the prevalence of ASB in children and adolescents with diabetes and healthy control subjects. Because the
heterogeneity test was not signiﬁcant (I
2,* P  0.51) the results of the ﬁxed-effects model are presented.
Figure 3—Forest plot of ﬁve studies on the prevalence of ASB in men with diabetes and healthy control subjects. Because the heterogeneity test was
not signiﬁcant (I2 25.6%, P  0.24) the results of the ﬁxed-effects model are presented.
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diabetes as outcomes.
Thelimitationsofthismeta-analysis
arise mainly from the difﬁculties in ob-
taining detailed information from the
articles included. We were not able to
perform all analyses separately for the
age-groups, sexes, or diabetes types.
Also, the methodological quality of the
majority of the studies included in this
meta-analysis was poor. Almost all
studies were performed among elderly
women with type 2 diabetes, and when-
ever there were men, adolescents, or
young adults included, the data for the
different patient groups were not possi-
ble to separate. Yet this meta-analysis
supports previous observations, veriﬁes
the incidence of ASB in the more sel-
dom–investigated patient groups, and
found signiﬁcant association between
albuminuria and ASB in patients with
diabetes.
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